Abstract:Abstract Background: Salt-inducible kinases (SIKs) belonging to an AMP-activated kinase (AMPK) family, have functions in tumourgeniesis and metastasis in many solid tumours. However, the role of SIKs in breast cancer is not clear. In this study we aimed to determine the function of SIKs (SIK1, SIK2 and SIK3) in human breast cancer. Method: A cohort of breast cancer tissues (n=102) were analysed using qPCR to determine changes in SIK expression (SIK1, SIK2, SIK3 and housekeeping GAPDH ) between cancer and normal tissues and different aetiologies of cancer. In addition, a breast disease spectrum array (TMA) was probed for SIK expression at the protein level. SIK1, 2 and 3 were knocked down using shRNA in the human breast cancer cell lines MCF-7 and MDA-MB-231 and changes in cell behaviour were assessed using a number of cell function assays.Results: At the messenger level, expression of SIK2 was lower in breast cancer than normal tissue (p=0.0179), while expression of SIK1 and SIK3 had no significant difference between breast cancer and normal tissue. SIK3 expression was associated with ER status in the cohort (p=0.02). The level of SIK2 expression was significantly different in Stage I and Stage III. While SIK3 expression was significantly higher in ER positive breast cancer than ER negative breast cancer. Further analysis using Kaplan-Meier survival was performed for SIKs expression in an online database (http://kmplot.com/analysis/index.php?p=background) which showed that that an increased expression of SIKs was associated with good prognosis in the breast cancer cohort (p<0.01). Moreover, IHC staining correlation of SIKs in tumour with different clinicopathological characteristics showed a SIK1 Klein score significantly higher in ER positive breast cancer than ER negative breast cancer; in SIK3, a higher Klein score was observed in breast cancer with higher Grade, negative lymph node and higher TNM stage (p <0.05). In vitro, reduced expression of SIK2 and SIK3 increases the proliferation of breast cancer cells. However, SIK2 and SIK3 had differential effects on breast cancer cell adhesion. Knockdown of SIK2 only enhanced the adhesion of triple negative breast cancer cells (MDA-MB-231), while knockdown of SIK3 decreased the adhesion of both MDA-MB-231 and MCF 7 cells. Knockdown of SIK1 and SIK3 increased the invasion of MDA-MB-231 cells (p<0.05). Knockdown SIK1 increased the barrier but knockdown of SIK2 and SIK3 decreased the barrier of the breast cancer cells (p<0.05). We also determined the effect of possible chemotherapeutic resistance in these cell lines: the cells were treated with various concentration of chemotherapy drugs and placebo and found that reduced SIKs increased the resistance of breast cancer cell to paclitaxel and cisplatin.Conclusion: In conclusion, we show that low expression of SIK1,2 and 3 in breast cancer was correlated with poor prognosis and chemotherapy resistance of breast cancer. Reduced SIKs promote tumour metastasis by enhancing tumour function and tight junction. SIKs could be potential biomarkers for prognosis and chemotherapy sensitivity in breast cancer. Citation Format: Ling Xin, Chang Liu, Yinhua Liu, Robert E. Mansel, Eleri Davies, Wen G. Jiang, Tracey A. Martin. Salt-inducible kinases suppress tumour function and regulate drug resistance in breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS4-41.

Clinical Implications of SIKs Expression in Gastric Cancer

The potent roles of salt-inducible kinases (SIKs) in metabolic homeostasis and tumorigenesis

Role of SIK1 in tumors: Emerging players and therapeutic potentials (Review)

Siks Suppress Tumor Function And Regulate Drug Resistance In Breast Cancer

Abstract PS4-41: Salt-inducible Kinases Suppress Tumour Function and Regulate Drug Resistance in Breast Cancer

Identification of Spindle and Kinetochore-Associated Family Genes As Therapeutic Targets and Prognostic Biomarkers in Pancreas Ductal Adenocarcinoma Microenvironment

SIK1 suppresses colorectal cancer metastasis and chemoresistance via the TGF-β signaling pathway

SIK2 represses AKT/GSK3β/β‐catenin signaling and suppresses gastric cancer by inhibiting autophagic degradation of protein phosphatases

SGK1 in Human Cancer: Emerging Roles and Mechanisms

Role of salt‑inducible kinase 2 in the malignant behavior and glycolysis of colorectal cancer cells

SIK2 Promotes Reprogramming of Glucose Metabolism Through PI3K/AKT/HIF-1α Pathway and Drp1-mediated Mitochondrial Fission in Ovarian Cancer.

Activation of STAT3 in Human Gastric Cancer Cells Via Interleukin (Il)-6-type Cytokine Signaling Correlates with Clinical Implications

Salt‐inducible kinase 2 functions as a tumor suppressor in hepatocellular carcinoma

Abstract 5147: Identification of pharmacodynamic biomarkers in PBMCs and cancer cells for SIK2 kinase inhibitor therapy

SIK2‐positive tumor epithelial cells in breast cancer maybe potential anti‐cancer messengers: A systematic analysis from a single‐cell perspective

Functional Roles of SPINK1 in Cancers

Clinicopathological significance of PI3K, Akt and survivin expression in gastric cancer.

The emerging double-edged sword role of Sirtuins in the gastric inflammation-carcinoma sequence revealed by bulk and single-cell transcriptomes

SP1 Mediated PIK3CB Upregulation Promotes Gastric Carcinogenesis

Understanding the roles of salt-inducible kinases in cardiometabolic disease

The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer